NADAC acquisition cost data for SIMVASTATIN 5 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 16714068101 | $0.0231 | 2022-12-21 | Rx |
| 16714068102 | $0.0231 | 2022-12-21 | Rx |
| 16729015615 | $0.0231 | 2022-12-21 | Rx |
| 16729015617 | $0.0231 | 2022-12-21 | Rx |
| 24658050010 | $0.0231 | 2022-12-21 | Rx |
| 24658050030 | $0.0231 | 2022-12-21 | Rx |
| 24658050090 | $0.0231 | 2022-12-21 | Rx |
| 31722051010 | $0.0231 | 2022-12-21 | Rx |
| 31722051090 | $0.0231 | 2022-12-21 | Rx |
| 55111019705 | $0.0231 | 2022-12-21 | Rx |
Generic: Simvastatin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $207.0M | 21,430,571 | 5,180,030 | $0.1383 |
| 2020 | $186.2M | 20,441,398 | 4,830,073 | $0.1251 |
| 2021 | $163.9M | 18,748,498 | 4,553,435 | $0.1181 |
| 2022 | $154.1M | 17,338,301 | 4,235,614 | $0.1189 |
| 2023 | $172.9M | 15,950,783 | 3,917,152 | $0.1438 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $19.6M | 1,474,006 | 391,111 |
| New York | $11.9M | 1,104,229 | 263,928 |
| Florida | $10.9M | 1,185,005 | 323,502 |
| Texas | $10.2M | 942,336 | 249,691 |
| Pennsylvania | $10.1M | 885,564 | 210,771 |
| Michigan | $8.5M | 628,422 | 155,657 |
| Illinois | $6.2M | 574,935 | 143,146 |
| Massachusetts | $6.1M | 467,568 | 116,172 |
| Ohio | $6.1M | 637,894 | 156,610 |
| Minnesota | $5.7M | 392,781 | 95,043 |
| North Carolina | $4.7M | 470,707 | 119,215 |
| New Jersey | $4.3M | 379,542 | 97,321 |
| Wisconsin | $3.9M | 359,997 | 89,165 |
| Georgia | $3.8M | 398,099 | 100,275 |
| Puerto Rico | $3.8M | 609,756 | 137,415 |
| Virginia | $3.3M | 342,147 | 88,786 |
| Tennessee | $3.3M | 348,276 | 86,605 |
| Arizona | $3.1M | 292,933 | 80,964 |
| Missouri | $3.0M | 314,046 | 74,945 |
| Washington | $2.9M | 257,574 | 67,233 |
| Indiana | $2.9M | 299,755 | 76,528 |
| Alabama | $2.7M | 226,546 | 57,654 |
| Colorado | $2.4M | 215,781 | 57,493 |
| Kentucky | $2.3M | 259,938 | 60,955 |
| South Carolina | $2.2M | 216,209 | 57,055 |
| Iowa | $2.1M | 224,278 | 53,758 |
| Oklahoma | $2.1M | 151,913 | 36,676 |
| Maryland | $2.0M | 169,513 | 45,327 |
| Oregon | $1.9M | 164,861 | 43,660 |
| Arkansas | $1.9M | 167,881 | 38,652 |
| Connecticut | $1.8M | 161,303 | 41,237 |
| Kansas | $1.6M | 171,596 | 40,729 |
| Louisiana | $1.5M | 172,525 | 40,754 |
| Nebraska | $1.2M | 115,275 | 25,921 |
| Utah | $1.2M | 97,247 | 26,070 |
| New Mexico | $1.1M | 86,349 | 23,559 |
| Mississippi | $1.1M | 111,660 | 26,543 |
| Hawaii | $970.0K | 56,399 | 15,804 |
| West Virginia | $938.9K | 106,839 | 26,838 |
| Maine | $933.4K | 87,916 | 23,621 |
| Nevada | $905.6K | 96,141 | 27,859 |
| New Hampshire | $820.8K | 71,534 | 19,006 |
| Rhode Island | $752.9K | 60,938 | 15,230 |
| Idaho | $675.7K | 72,088 | 18,907 |
| North Dakota | $592.9K | 57,571 | 12,861 |
| Montana | $567.9K | 59,064 | 14,333 |
| Vermont | $527.2K | 40,312 | 10,131 |
| South Dakota | $508.0K | 57,251 | 12,922 |
| Delaware | $474.4K | 41,914 | 11,587 |
| Wyoming | $261.2K | 22,606 | 5,972 |
| Alaska | $200.8K | 12,323 | 3,221 |
| District of Columbia | $197.8K | 16,620 | 4,876 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.